Does RGNT pay a dividend and is it safe?

Regentis Biomaterials Ltd. (RGNT) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / RGNT / dividends

CLGN (41) CUPR (21) HSCS (38) LFWD (32) ⌘ Pro Terminal →

Regentis Biomaterials Ltd. (RGNT) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.37 0.00% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.37

Regentis Biomaterials Ltd. (RGNT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $9.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RGNT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RGNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Regentis Biomaterials Ltd. (NYSE: RGNT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.37 (0.00% 1D, market cap $9.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RGNT ranks #777 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RGNT compare to CLGN and CUPR in the Health Care sector?

▼

Within the Health Care sector (Industrial Specialties), RGNT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, RGNT leads on earnings multiple (N/A) while RGNT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RGNT?

▼

Per RGNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001912966), Regentis Biomaterials Ltd. generated $19.5M in revenue (+647.6% YoY), -$13.6M in net income, and -$1.4M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.37 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RGNT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY RGNT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.63-9.8% Next Q

Q2 (-2Q)

Grade E$1.47-12.2% Next Q

Q3 (-1Q)

Grade E$1.29+6.2% Next Q

Current

Grade E$1.37-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RGNT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RGNT currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.75) and Max Pain ($1.44) forces dealer call-delta covering toward $16.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RGNT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RGNT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RGNT)

✓Walkthrough of RGNT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RGNT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.27%🛡️ HOLDING TREND SUPPORT

2026-11-03O $1.36H $1.37L $1.36C $1.37VOL 24.9K

RES: $2.68SUP: $1.20SMA50: $1.75SMA200: $2.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RGNT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RGNT Butterfly Map → + Track RGNT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +647.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RGNT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RGNT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RGNT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RGNT)

Health Care Rank #777 of 1015 ⚔️ CLGN vs RGNT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RGNT vs. CLGN, CUPR, HSCS, LFWD)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Regentis Biomaterials Ltd. (RGNT) ranks #777 by composite RQD confidence (31/100, grade E) and #896 by equity capitalization ($9.6M). Within this direct 5-issuer industry benchmark cohort, RGNT leads on earnings valuation at N/A trailing P/E, while RGNT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with RGNT at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RGNT ACTIVE Regentis Biomaterials Ltd.	E	31/100	—	—	-35.0%	0.00%	$9.6M	Benchmark Subject
CLGN CollPlant Biotechnologies Ltd	D-	41/100	—	64.8%	-35.0%	-1.33%	$11.9M	/clgn-vs-rgnt →
CUPR Cuprina Holdings (Cayman) Limited (Class A)	E	21/100	—	-1.3%	-35.0%	+3.96%	$13.5M	/cupr-vs-rgnt →
HSCS HeartSciences Inc.	D-	38/100	—	59.1%	-35.0%	-9.67%	$16.0M	/hscs-vs-rgnt →
LFWD Lifeward Ltd.	E	32/100	—	96.0%	-35.0%	+1.82%	$16.9M	/lfwd-vs-rgnt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001912966 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Regentis Biomaterials Ltd. (RGNT) reported GAAP revenue of $19.5M (+647.6% vs. FY2024 revenue of $2.6M , and +260.8% cumulative change since FY2023) , GAAP net income of -$13.6M, operating cash flow of -$1.4M, and free cash flow of -$1.4M (-114.5% YoY). On the balance sheet, RGNT closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$19.5M	-$13.6M	-$1.4M	-$1.4M	$7.6M	—
FY2024 (FY)	2024-12-31	$2.6M	$4.8M	-$641.0K	-$641.0K	$482.0K	—
FY2023 (FY)	2023-12-31	$5.4M	-$4.1M	-$1.2M	-$1.2M	—	—

3. RGNT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RGNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RGNT compare to CLGN and CUPR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RGNT?

Where is RGNT trading relative to its 50-day, 200-day, and 52-week technical levels?

RGNT last traded at $1.37 (0.00% on volume of 15,303 shares), positioning the stock -21.71% below its 50-day simple moving average ($1.75) and -52.10% below its 200-day simple moving average ($2.86). Across its 52-week range of $1.23 to $15.50, RGNT sits at the 1.0% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).

Direct Sub-Reports: RGNT RQD Cockpit RGNT 12M Forecast RGNT Earnings & Move RGNT Dividends & DRIP RGNT Insiders & 13F RGNT Whale Options RGNT Profit Sankey RGNT News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

RGNT — Regentis Biomaterials Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Regentis Biomaterials Ltd. (RGNT) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.37 (0.00% 1D, market capitalization $9.6M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -14.39%.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Regentis Biomaterials Ltd. (RGNT) is a NYSE-listed issuer classified in the Health Care sector and the Industrial Specialties industry. Reported revenue is — in each period shown in the SEC financials, so the source does not establish how the company generates income. Market capitalization is listed as $9.6M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Regentis Biomaterials Ltd. (RGNT) reported $19.5M in annual revenue (up from $2.6M in FY2024, +647.6% YoY) and -$13.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.4M revenue, -$4.1M net income) through FY2025, RGNT scaled operating cash flow to -$1.4M and free cash flow to -$1.4M, backed by $7.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -14.39% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.23 – $15.50 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream suppliers, downstream customers, or sector correlations are identified in the source data. A prospective investor should therefore note that second-order ripple effects cannot be mapped from the available sources; any sector read-through would require information not present here.

Key Question #1: Can RGNT sustain or expand its — operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $19.5M and free cash flow of -$1.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is RGNT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RGNT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Regentis Biomaterials Ltd. (RGNT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RGNT Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 1d ago

Regentis Biomaterials (RGNT) Stock Forecast & Analyst Ratings

Moomoo report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal

Yahoo Finance report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Regentis Biomaterials (RGNT) Edges Lower: Shares Slip 0.67% to $1.48 - Low Vol Factor

https://www.siam.in/ report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Regentis Biomaterials Ltd. (RGNT) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE citybuzz - • 1d ago

Regentis Biomaterials' GelrinC Shows Promise in Cartilage Repair as Company Eyes FDA Approval

citybuzz - report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Menafn • 2d ago

Regentis Biomaterials (NYSE American: RGNT) To Present At 2026 Thinkequity Conference On Oct. 15

Menafn report covering Regentis Biomaterials Ltd. (RGNT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RGNT Bull vs. Bear Conversation Board — What's Your Call at $1.37?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RGNT 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $1.59 (+16.1%)

📌 Pinned Debate

Surgeon interest in GelrinC reported at the 8th ICRS Summit gives a possible commercial catalyst, and FY 2024 showed positive net incom

Picked up a starter position in RGNT in my $100K Virtual Cash book at $1.37. Surgeon interest in GelrinC reported at the 8th ICRS Summit gives a possible commercial catalyst, and FY 2024 showed positive net income of $4.8M.. Trading inside a $1.23–$15.50 52-week range with -14.39% FCF yield gives solid downside support if Industrial Specialties multiples expand this quarter.

SectorRotator 🐂 BULL

@DeltaGamma_99 Agree on the RQD 31/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.37 and keeping dry powder in case we test $1.27.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.08 (-21.2%)

Spot @ $1.37

ROIC of -35%, FCF yield of -14.39%, and an FY 2025 net loss of -$13.6M with a Piotroski F-Score of 1/9 point to weakening fundamentals.

ROIC of -35%, FCF yield of -14.39%, and an FY 2025 net loss of -$13.6M with a Piotroski F-Score of 1/9 point to weakening fundamentals.. Look at the math on RGNT: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $1.21 before getting long.